COVID-19 UPDATES


Image

Omicron



COVID-19 vaccines for children
Pfizer has published trial results for 5-11 year olds – two 10ug doses given 21 days apart was “found to be safe, immunogenic, and efficacious”. A review of pre- and post-marketing evidence on the benefit–risk profile of COVID-19 vaccines in children, pregnancy and other vulnerable groups, summarises current recommendations of scientific societies and regulatory agencies.

The Taskforce Paediatric and Adolescent Care Panel has reviewed the adult recommendations on the use of casirivimab plus imdevimab (Ronapreve/REGEN-COV) in patients with mild COVID-19 and the use of pulse oximeters in the context of children and adolescent care. The Taskforce now makes the following consensus recommendations:


COVID-19 in Australia
ICU capacity is currently lower than in 2020, and is constrained by the availability of trained staff - fewer than half of ICU beds could be opened. Stephen J Duckett and Brett Sutton discuss the need for a planned recovery from the pandemic, including managing health system capacity.


The National COVID-19 Clinical Evidence Taskforce has published a new assessment flowchart, Pathways to Care for Adults with COVID-19.  This update is part of an ongoing review of all 11 clinical flowcharts, with the Management of adults with mild COVID-19 and Management of adults with moderate to severe COVID-19 flowcharts next to be revised.


ICU management for COVID-19
International experts have reached consensus on 31 statements on infection control of SARS-CoV-2 in ICUs, covering design & engineering, health-care worker safety, visiting policy, patients & procedures, disinfection, and sterilisation. In Italy’s second wave lower ICU capacity strain and timelier admission may have played a role in reduced COVID-19 mortality.


Latest on vaccines
Pfizer vaccine efficacy in preventing COVID-19 declined approximately 6% every 2 months, peaking at 96.2% during the first two months and declining to 83.7% at six months. There is a correlation between time-from-vaccine and protection against infection – there was a 1.51-fold increased risk of breakthrough infection for early vaccinees compared with 4 months later.

Vaccines and long COVID: Vaccines reduce the risk of developing COVID-19 — but studies disagree on their protective effect against long-lasting symptoms that can follow the disease. Understanding the prevalence of long COVID among vaccinated people has urgent implications in places where public-health restrictions are being eased. It could also offer clues about what causes lingering illness long after the acute infection has cleared.

See the latest COVID-19 Updates from the European Medicines Agency


Remember to check EKS COVID-19 Updates, and Epworth's IPAC intranet page.

Published on 26/08/2021 00:00 • Show all news
Log in to your account:

Students - must register here to borrow books.  Remember to confirm your registration in order to checkout.

Online resources are available via your university or Epworth computers.

 

 

Don't have an account? Register here.

Links

Hosted by Prosentient